Hyperhomocysteinemia and Associated Biological Markers in a Congolese Population of Type 2 Diabetes Mellitus in Brazzaville  

作　　者：V. R. Ikia Monde A. L. M. Boumba E. Mokondjimobe H. Poaty G. Loubano-Voumbi W. F. Ondongo A. G. Mayindou Kimbangu K. Onanga F. Elilie Mawa Ongoth E. Bouenizabila C. Andres H. G. Monabeka V. R. Ikia Monde;A. L. M. Boumba;E. Mokondjimobe;H. Poaty;G. Loubano-Voumbi;W. F. Ondongo;A. G. Mayindou Kimbangu;K. Onanga;F. Elilie Mawa Ongoth;E. Bouenizabila;C. Andres;H. G. Monabeka(Biochemistry Laboratory Service, University Hospital Center, Brazzaville, Congo;Faculty of Health Sciences, Marien NGOUABI University, Brazzaville, Congo;Research Area of Pointe-Noire, National Institute for Research in Health Sciences (IRSSA), Pointe-Noire, Congo;Microbiology and Molecular Biology Department, Loandjili General Hospital, Pointe-Noire, Congo;LOMO Research University, Kinshasa, DRC;Department of Statistics, Health Information and Epidemiology Surveillance, Departmental Directorate of Health Care and Services, Brazzaville, Congo;Department of Endocrinology, University Hospital Center, Brazzaville, Congo;Department of Biochemistry and Molecular Biology, Bretonneau Regional University Hospital, Tours, France)

机构地区：[1]Biochemistry Laboratory Service, University Hospital Center, Brazzaville, Congo [2]Faculty of Health Sciences, Marien NGOUABI University, Brazzaville, Congo [3]Research Area of Pointe-Noire, National Institute for Research in Health Sciences (IRSSA), Pointe-Noire, Congo [4]Microbiology and Molecular Biology Department, Loandjili General Hospital, Pointe-Noire, Congo [5]LOMO Research University, Kinshasa, DRC [6]Department of Statistics, Health Information and Epidemiology Surveillance, Departmental Directorate of Health Care and Services, Brazzaville, Congo [7]Department of Endocrinology, University Hospital Center, Brazzaville, Congo [8]Department of Biochemistry and Molecular Biology, Bretonneau Regional University Hospital, Tours, France

出　　处：《Open Journal of Endocrine and Metabolic Diseases》2024年第6期123-134,共12页内分泌与新陈代谢疾病期刊（英文）

摘　　要：The search for new biomarkers predictive of type 2 diabetes currently constitutes a research avenue in Bioclinical. Total homocysteine remains a preferred target due to its involvement in the occurrence of degenerative complications in type 2 diabetics. The aim of this work was to study hyperhomocysteinemia and other biochemical markers associated with T2D in the Congolese population. This was an analytical case-control study carried out between October 2022 and October 2023. The study population consisted of 150 subjects including 100 T2D patients and 50 control subjects. The main clinical data were collected on a pre-established form. Homocysteine determination was carried out by the sandwich ELISA method. The other biochemical markers were measured by colorimetric enzymatic methods. Hyperhomocysteinemia was present in 27.3% (41/150) of the entire study population. Type 2 diabetics had a frequency of hyperhomocysteinemia of 36% (36/100) and control 10% (5/50) (p = 0.001). The mean hyperhomocysteinemia concentration was 31.9 μmol/l with extremes ranging from 18 to 103 μmol/l. Means of biological markers between diabetics and controls showed a statistically significant difference (p = 0.01). The risk factors associated with this HHcy were: sex (OR = 3.5), age (OR = 9.4), sedentary lifestyle (OR = 3.4) and glycosylated hemoglobin (OR = 12) with a p-value <0.05 respectively. Our results suggest that hyperhomocysteinemia can be considered as a predictive biomarker in the bioclinic of Congolese type 2 diabetic patients.The search for new biomarkers predictive of type 2 diabetes currently constitutes a research avenue in Bioclinical. Total homocysteine remains a preferred target due to its involvement in the occurrence of degenerative complications in type 2 diabetics. The aim of this work was to study hyperhomocysteinemia and other biochemical markers associated with T2D in the Congolese population. This was an analytical case-control study carried out between October 2022 and October 2023. The study population consisted of 150 subjects including 100 T2D patients and 50 control subjects. The main clinical data were collected on a pre-established form. Homocysteine determination was carried out by the sandwich ELISA method. The other biochemical markers were measured by colorimetric enzymatic methods. Hyperhomocysteinemia was present in 27.3% (41/150) of the entire study population. Type 2 diabetics had a frequency of hyperhomocysteinemia of 36% (36/100) and control 10% (5/50) (p = 0.001). The mean hyperhomocysteinemia concentration was 31.9 μmol/l with extremes ranging from 18 to 103 μmol/l. Means of biological markers between diabetics and controls showed a statistically significant difference (p = 0.01). The risk factors associated with this HHcy were: sex (OR = 3.5), age (OR = 9.4), sedentary lifestyle (OR = 3.4) and glycosylated hemoglobin (OR = 12) with a p-value <0.05 respectively. Our results suggest that hyperhomocysteinemia can be considered as a predictive biomarker in the bioclinic of Congolese type 2 diabetic patients.

关 键 词：HYPERHOMOCYSTEINEMIA Biological Markers T2DM BRAZZAVILLE 

分 类 号：R58[医药卫生—内分泌]